Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic characterization of thymic epithelial tumors in a real-world dataset.
Kurokawa K, Shukuya T, Greenstein RA, Kaplan BG, Wakelee H, Ross JS, Miura K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi K. Kurokawa K, et al. Among authors: wakelee h. ESMO Open. 2023 Oct;8(5):101627. doi: 10.1016/j.esmoop.2023.101627. Epub 2023 Sep 12. ESMO Open. 2023. PMID: 37703595 Free PMC article.
THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY.
Ivanovic M, Chan A, Cheng E, Xu S, Lee C, You J, Franquiz M, Fazal M, Batchelder R, Wu SM, Reddy SA, Katsumoto T, Ramchandran K, Colevas AD, Khan SA, Fan AC, Cheng P, Wakelee H, Witteles R, Neal JW, Waliany S, Zhu H. Ivanovic M, et al. Among authors: wakelee h. medRxiv [Preprint]. 2024 Jan 24:2024.01.22.24301442. doi: 10.1101/2024.01.22.24301442. medRxiv. 2024. PMID: 38343840 Free PMC article. Preprint.
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
Beckermann KE, Bestvina CM, El Osta B, Sanborn RE, Borghaei H, Lammers PE, Selvaggi G, Whisenant JG, Heimann-Nichols E, Berry L, Hsu CY, Shyr Y, Horn L, Wakelee H. Beckermann KE, et al. Among authors: wakelee h. JTO Clin Res Rep. 2023 Dec 15;5(2):100619. doi: 10.1016/j.jtocrr.2023.100619. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38328473 Free PMC article.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Nassar AH, et al. Among authors: wakelee ha. J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032-7. doi: 10.1016/j.jtho.2024.01.012. Online ahead of print. J Thorac Oncol. 2024. PMID: 38278303
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui C, Brown E, Wong S, Das M, Wakelee H, Neal J, Ramchandran K, Myall NJ, Pham D, Xing L, Yang Y, Kovalchuk N, Yuan Y, Lu Y, Xiang M, Chin A, Diehn M, Loo BW Jr, Vitzthum LK. Hui C, et al. Among authors: wakelee h. Clin Lung Cancer. 2024 Mar;25(2):186-189. doi: 10.1016/j.cllc.2023.11.004. Epub 2023 Nov 8. Clin Lung Cancer. 2024. PMID: 38040540
343 results